These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 36681775

  • 1. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
    Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illes A, Ozkurt ZN, Snowden JA, Arat M, Bulabois CE, Niederland J, Sever M, Paneesha S, Potter V, Gadisseur A, Chalopin T, Van Gorkom G, López JM, Kerre T, Drozd-Sokolowska J, Raj K, Hayden PJ, Beksac M, Yakoub-Agha I, McLornan DP, Schönland S.
    Bone Marrow Transplant; 2023 Apr; 58(4):424-429. PubMed ID: 36681775
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
    Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, Sawa M, Kataoka K, Hiramoto N, Ota S, Itagaki M, Ichinohe T, Atsuta Y, Yano S, Kawamura K, working group of the Japan Society for Transplantation and Cellular Therapy.
    Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
    [Abstract] [Full Text] [Related]

  • 5. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    Lee BH, Shin SH, Min CK, Yhim HY, Kwak JY, Kim JA.
    Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
    [Abstract] [Full Text] [Related]

  • 6. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY, Wang HF, Xia LH, Wang QQ, Qian CJ, He J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [Abstract] [Full Text] [Related]

  • 7. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
    Wu Q, Liu JR, Huang BH, Zou WY, Gu JL, Chen ML, Kuang LF, Zheng D, Xu DR, Zhou ZH, Wang HH, Su C, Tong XZ, Li J.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun 14; 40(6):453-459. PubMed ID: 31340616
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
    Guman T, Sykora J.
    Bratisl Lek Listy; 2024 Jun 14; 125(1):9-11. PubMed ID: 38041839
    [Abstract] [Full Text] [Related]

  • 11. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M.
    Intern Med; 2013 Jun 14; 52(9):961-8. PubMed ID: 23648714
    [Abstract] [Full Text] [Related]

  • 12. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 14; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy].
    Tsukada N, Oda Y, Nomura M, Kasuya Y, Takei T, Sato K, Ogura M, Kikuchi T, Abe Y, Suzuki K, Ishida T.
    Rinsho Ketsueki; 2023 Apr 14; 64(11):1397-1403. PubMed ID: 38072424
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 14; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 19. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H, Atrash S, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cui W, McGuirk J, Shune L, Ahmed N, Abdallah AO.
    Transplant Cell Ther; 2023 Apr 14; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.